SMN1 and proximal spinal muscular atrophy: Genome editing of SMN2, which is present in all SMA patients regardless of the nature of their SMN1 mutation, could enable a one-time treatment for SMA that restores native SMN transcript and protein levels while preserving their endogenous regulatory mechanisms.